Abstract Extensive investigations have shown that miRNAs are important regulators of epithelial-to-mesenchymal transition (EMT), mainly targeting the transcriptional repressors of E-cadherin (E-cad). Less is known about
Introduction
Epithelial ovarian cancer (EOC) remains the most lethal gynaecological malignancy [1] . The majority of EOC patients are diagnosed at advanced stages and the overall 5-year survival rate is around 40% [2] . Although EOC is a heterogeneous disease, the standard treatment for EOC patients remains a combination of cytoreductive surgery and platinum-based chemotherapy [2] . Many targeted therapies, including anti-angiogenic agents and PARP inhibitors, are currently under evaluation in phase I/II and III studies [3] [4] [5] [6] .
Epithelial-to-mesenchymal transition (EMT) is a well-recognized dedifferentiation process that is critical for epithelial cancer metastasis [7] . Therefore, EOC patients may benefit from targeted therapies that inhibit EMT. The process of EMT is highly coordinated and involves complex gene expression reprograming [8, 9] . The molecular hallmarks of EMT include down-regulation of E-cadherin (E-cad), which is responsible for cell-cell adhesion, and up-regulation of mesenchymal proteins, such as vimentin and N-cadherin (N-cad). E-cad has been the focus of EMT regulation and is considered a driver for this process [8, [10] [11] [12] [13] . In contrast, vimentin and N-cad, although they are evaluated in almost all EMT studies, have been considered as markers with a functional role not well understood.
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transcriptome by binding to the 3'-untranslated region (3'-UTR) of target genes, leading to either mRNA degradation or inhibition of protein translation [15] . Increasing evidence has demonstrated that miRNAs are highly deregulated in cancer, suggesting that they function as therapeutic targets [16, 17] . Extensive investigations have shown that miRNAs are important regulators of EMT and mainly target E-cad transcription repressors, such as the let-7 and miR-200 miRNA families [18, 19] . Recently, miR-30a and miR-138 were shown to directly target VIM [20, 21] . Few miRNAs have been reported to regulate both E-cad and mesenchymal proteins.
Our recent investigation of the EMT regulatory network in the serous subtype of EOC characterized miR-506 as a robust EMT inhibitor through directly targeting the E-cad repressor SNAI2 [14] . In further computational analyses, we found a single miR-506 binding site in the 3'-UTRs of both the vimentin gene (VIM) and the N-cad gene (CDH2), suggesting that miR-506 is a member of a new class of EMT regulatory miRNAs that affect multiple targets in EMT processes. Here we provide experimental evidence that miR-506 directly targets vimentin and N-cad.
Materials and methods

MiRNA transfection and siRNA transfection
The miRNA mimics of miR-506 and negative controls were obtained from Dharmacon (Chicago, IL, USA). Cells were seeded at 2 × 10 5 per well in six-well plates and allowed to attach for at least 16 h. MiR-506 mimic or negative control was transfected using lipofectamine RNAiMAX (Invitrogen, Carlsbad, CA, USA) at a final concentration of 50 nM.
SiRNAs against vimentin (ID # s14799 and s14800) were purchased from Ambion (Grand Island, NY, USA) by Life Technologies. The siRNA transfection was performed the same way as that for miRNAs, as described above. The final siRNA concentration was 50 nM. For the sustained siRNA knockdown experiments, the cells were transfected with the siRNA three times in a 4-day interval. The cells were split at a 1 : 2 ratio at 3 days post-transfection.
Western blot analysis
Primary antibodies of β-actin and vimentin were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA), Sigma (Woodlands, TX, USA), or Novocastra (Newcastle Upon Tyne, UK). N-cadherin antibodies were purchased from Cell Signaling Technology (Boston, MA, USA) or BD Transduction Laboratories (San José, CA, USA). A Western blot analysis was performed as described previously [14] . The detailed method can be found in the Supplementary materials and methods.
Immunofluorescence staining and confocal imaging
Cells were seeded into 15 μ-Slide VI purchased from ibidi (Verona, WI, USA) (# 80602) and cultured in complete medium. Cells were fixed in 4% paraformaldehyde for 15 min, followed by permeabilization in 1× PBS containing 0.5% NP40 for 30 min at ambient temperature. The cells were blocked in blocking solution (1× PBS containing 10% normal goat serum and 0.5% NP40) for at least 4 h and incubated with a mouse monoclonal anti-human E-cad or vimentin antibody (1 : 200 dilution) at 4 ∘ C overnight. After being washed, the cells were incubated with a goat anti-mouse IgG conjugated with Alexa Fluor 488 (Invitrogen, #A11029) (1 : 1000 dilution) at ambient temperature for 1 h. F-actin was stained with phalloidin-TRITC (Molecular Probes, Grand Island, NY, USA) at a concentration of 0.5 μg/ml and incubated at ambient temperature for 45 min. The images were taken by an Olympus FV1000 laser confocal microscope. Phase images were captured using a Zeiss HAL 100 microscope.
MiR-506 binding site deletion and luciferase reporter assay
The 3'-UTR of VIM that contains the predicted binding site of miR-506 was amplified from normal fetal genomic DNA by PCR using specific primers (Supplementary materials and methods). The PCR product was cloned into the pGL3-control vector at the XbaI site in the correct direction. The consensus miR-506 binding site was deleted by PCR using a QuikChange II XL site-directed mutagenesis kit (Stratagen, Santa Clara, CA, USA). All clones were verified by DNA sequencing. For the luciferase reporter assay, subconfluent SKOV3 cells in 12-well plates were transfected with a triplicate repeat of pGL3 reporter plasmid (0.5 μg), pRL-TK (20 ng), miRmimics or negative controls (50 nM), and lipofectamine 2000 (2 μl) (Invitrogen). Twenty-four hours after transfection, cells were lysed and luciferase activities were determined as for a dual-luciferase assay reporter system (Promega, Madison, WI, USA), according to the manufacturer's instructions.
A 25 bp region of the 3'-UTR CDH2 gene containing the miR-506 seed region was cloned in the pmirGLO Dual-Luciferase miRNA Target Expression Vector (Promega) according to the manufacturer's instructions. The specific primer sequences can be found in the Supplementary materials and methods. All clones were verified by DNA sequencing. For the luciferase assay, 5 × 10 4 HEK293T and OAW42 cells were seeded in triplicate in 24-well plates and transfected for 24 h with pmirGLO vector (1 μg) together with 50 nM miR-506 mimics, unrelated miR, or scrambled miR as a negative control. 35-mm high Culture-Insert (ibidi) and cultured for 24 h. The wound was then applied and phase-microscopy imaging was performed at different time periods. The cell invasion assay was performed in duplicate using Matrigel-coated transwell chambers (8-μm pore size, BD). The cells were plated in 500 μl of serum-free medium (4 × 10 4 cells per transwell) and allowed to invade towards a 10% FBS medium for 20 h. Cells that invaded into the underside of the filter were fixed and stained with HEMA-DIFF solution (Fisher, Waltham, MA, USA). The numbers of invaded cells from five randomly chosen fields were counted for each membrane.
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Patient tissue samples and tissue microarray construction
We collected paraffin-embedded tissue from 204 EOC cases from Tianjin Medical University Cancer Institute and Hospital after we received approval from the institutional review board. The clinical characteristics of the cases are listed in Table 1 . These samples were collected for tissue microarray (TMA) analyses. TMAs were constructed using a manual tissue microarray instrument (Beecher Instruments Inc., Sun Prairie, WI, USA) equipped with a 2.0-mm punch needle, as described in a previous study [14] .
MiRNA in situ hybridization
MiRNA in situ hybridization (ISH) was performed as described previously [14] . The TMA slides were hybridized with the double-DIG-labelled miRCURY LNA TM detection probe, hsa-miR-506 (38314-15, Exiqon, Woburn, MA, USA), for 2 h at 55 ∘ C (Ventana Discovery Ultra). The digoxigenins were detected with a polyclonal anti-DIG antibody and an alkaline phosphatase-conjugated second antibody (Ventana), using NBT-BCIP as the substrate. The LNA U6 snRNA probe was used as a positive control for every TMA core. Signals in tumour cells were quantified as described previously [14] , using a scoring system from 0 to 9, multiplied signal intensity, and the percentage of positive cells (signal: 0 = no signal, 1 = weak signal, 2 = intermediate signal, and 3 = strong signal; percentage: 0 = 0%, 1 = < 25%, 2 = 25-50%, and 3 = > 50%). Low and high MiR-506 expression levels were defined as scores of < 6 and ≥ 6, respectively.
Immunohistochemical analysis
Immunohistochemical staining was performed with the mouse anti-human N-cadherin (1 : 100, 3B9; Invitrogen), mouse anti-human vimentin (1 : 50, V9; Santa Cruz), rabbit anti-human SNAI2 (1 : 10, C19G7; Cell Signaling Technology), and rabbit anti-human E-cadherin (1 : 100, H-108; Santa Cruz) antibodies on TMA sections after antigen retrieval. Dako EnVision + System-HRP (DAB) kits were used. For the negative controls, the primary antibodies were replaced with PBS. N-cadherin-and vimentin-positive cells were defined as those with brown staining in the cytoplasm, whereas SNAI2-and E-cadherin-positive cells were defined as those with brown staining in the nucleus and cell membrane, respectively. Signals in tumour cells were quantified using the same scoring system (0-9) as that for miRNA ISH, described above.
Liposomal preparation
MiRNA for in vivo delivery was incorporated into DOPC (1,2-dioleoyl-sn-glycero-3-phosphatidylcholine) as previously described [14] . DOPC and miRNA were mixed in the presence of excess tertiary butanol at a ratio of 1 : 10 (w/w) miRNA/DOPC. Tween 20 was added to the mixture of Tween 20 and miRNA/DOPC in a ratio of 1 : 19. The mixture was vortexed, frozen in an acetone/dry ice bath, and lyophilized. Before in vivo administration, the preparation was hydrated with PBS at ambient temperature at a concentration of 200 μg/kg per injection.
Animals, orthotopic models, and tissue processing Tumour tissue was snap-frozen or fixed in formalin. Haematoxylin and eosin (H&E) and immunohistochemical staining was performed. For immunohistochemical staining, rabbit anti-human polyclonal antibody against N-cad (1 : 250; Boster Biological Technology, Wuhan, China) and Dako EnVision + System-HRP Rabbit (DAB) were used. The calculation method for N-cad was the same as that for TMA, as described above.
Statistical analysis
Student's t-test, chi-square test, Fisher's exact test, Kaplan-Meier analyses, and log-rank tests were performed using SPSS software version 17.0. Significance was defined as p < 0.05.
Results
MiR-506 directly targets VIM and CDH2 expression through 3'-untranslated regions
An examination of seven publicly available miRNA target gene databases revealed that VIM and CDH2 had one predicted binding site of miR-506 ( Figure 1A ). Transfection of miR-506 mimic in three EOC cell lines led to decreased VIM and N-cad protein levels ( Figure 1B ). To determine whether miR-506 regulates VIM through binding to its 3'-UTR, we cloned the VIM 3'-UTR into the pmirGLO luciferase reporter vector and transfected the pmirGLO vector or the parent luciferase expression vector, with miR-506 mimic or miR-Ctrl, into SKOV3 cells. Co-transfection of pmirGLO-VIM-3'-UTR and miR-506 mimic resulted in luciferase activity lower than that in the cells co-transfected with miR-Ctrl (p = 0.009, Figure 1C ), suggesting that miR-506 directly targets VIM. To confirm that miR-506 specifically regulates VIM, we generated the construct pmirGLO-VIM-3'-UTR-mutant in which the miR-506 binding site sequence on the 3'-UTR was deleted. These constructs were then co-transfected with miR-506 mimic or miR-Ctrl into SKOV3 cells. Deletion of the miR-506 binding site from the 3'-UTRs abolished the effects of miR-506 on luciferase activity ( Figure 1C) . For CDH2 targeting, we cloned a small region of 25 bp that contained the miR-506 seed into the pmirGLO vector to avoid interference with other miRNAs that may target the 3'-UTR of CDH2. HEK293T cells and the OAW42 EOC cell line were then transfected with reporter plasmid alone or in association with a scrambled miR, miR-506 mimic, or unrelated miR. A significant decrease in luciferase activity was observed in miR-506-transfected cells, demonstrating direct binding of the selected miRNA within the predicted 3'-UTR of CDH2 ( Figure 1D ).
Attenuation of vimentin induces epithelial characteristics and suppresses cell migration and invasion
Vimentin is an intermediate cell filament protein that is commonly considered as a mesenchymal marker. Vimentin's functional role in the EMT process is not well understood. To gain insight into the vimentin's function, we treated OVCA433 ovarian cancer (OvCa) cells with siRNAs against vimentin. As shown in Figure 2A , at 72 h after transfection, both siRNAs led to a significant decrease of vimentin compared with that in the si-control transfected cells (Figure 2A) . Interestingly, E-cadherin levels in the transfected cells were increased (Figure 2A ). An immunofluorescence staining analysis showed that the cells with significantly low levels of vimentin exhibited epithelial cell morphological characteristics, characterized by plump and aggregated cells and a cortical f-actin staining pattern ( Figure 2B , upper panel, arrows). On the other hand, a fraction of cells with relatively high levels of vimentin still showed the mesenchymal phenotype, characterized by spreading growth and the mesenchymal f-actin staining pattern ( Figure 2B , upper panel, arrowheads). The cells transfected with si-VIM exhibited intense E-cad expression on cell membranes in cell-cell junctions ( Figure 2B , lower panel). In the wound healing assay, we observed moderate inhibition of cell migration at 72 h after si-VIM treatment ( Figure 2C) .
We next performed a sustained knockdown of vimentin by continually transfecting the siRNAs to the OVCA433 cells for 12 days (three times in a 4-day interval). The majority of si-VIM transfected cells showed undetectable levels of vimentin ( Figure 2D , upper panel) and marked epithelial honeycomb morphological characteristics, characterized by the co-localization of E-cad and f-actin in the cell-cell junctions ( Figure 2D , lower panel). Consistently, we observed a significant inhibition of cell migration and invasion after the sustained knockdown of vimentin ( Figures 2E and 2F) . Similar results were observed in SKOV3 cells ( Figures 2G and  2H) . In contrast to the results of siRNA experiments for vimentin, we did not observe marked changes in cell migration and invasion when we treated SKOV3 cells with siRNA for N-cad.
MiRNA-506 expression is associated with decreased vimentin, N-cad, and SNAI2 expression and increased E-cad expression in all major subtypes of EOC In our previous study, we reported that miR-506 levels, as quantified by real-time PCR, were consistent with miR-506 ISH results and associated with decreased SNAI2 and vimentin and increased E-cad expression in high-grade serous OvCa [14] . In this study, with a comprehensive TMA, we quantified the expression of miR-506, control U6 small RNA, vimentin, N-cad, SNAI2, and E-cad in the tumour cells of 204 EOCs Images were taken at 0 h and 7 h after wound application. Scale bars = 500 μm. (D) The sustained knockdown of vimentin induces membrane E-cad expression, strengthens cell-cell adherence, and promotes epithelial morphological characteristics. OVCA433 cells were transfected with si-Ctrl, si-VIM #1, or si-VIM #2 three times in a 4-day interval. At day 11 after transfection, OVCA433 cells were fixed and stained with vimentin/f-actin or E-cad/f-actin. Cell nuclei were stained with DAPI. Scale bars = 20 μm. (E) The sustained knockdown of vimentin dramatically inhibits cell migration. OVCA433 cells were from the same transfection as in D. At day 11 after transfection, the cells were seeded into a wound healing assay chamber and images were taken at 0 h and 7 h after wound application. Scale bars = 500 μm. (F) The sustained knockdown of vimentin significantly inhibits cell invasion. OVCA433 cells from the same transfection as in D were seeded into transwell invasion chambers (n = 3) and allowed to invade for 20 h. The cells that invaded the lower side of the transwell membrane were fixed and stained. The bar graph was generated by means ± SD from duplicate transwells for each group. * p < 0.001. (G) Sustained knockdown of vimentin up-regulates E-cad protein expression in SKOV3 cells. SKOV3 cells were transfected with si-Ctrl, si-VIM #1, or si-VIM #2 as in D. At day 11 post-transfection, cell lysate was collected and the expression of vimentin and E-cad was detected using a western blot analysis. Actin was used as a control. (H) Sustained knockdown of vimentin inhibits SKOV3 migration. SKOV3 cells were transfected as in G. At day 11 post-transfection, SKOV3 cells were seeded into a wound healing assay chamber and cultured for 12 h. Images were taken at 0 h and 5 h after wound application. Scale bars = 500 μm. Figure 3 . High miR-506 expression is associated with decreased N-cad, vimentin, and SNAI2 expression and increased E-cad expression in all major subtypes of EOC. MiR-506 ISH was performed using the double-DIG-labelled miRCURY LNA TM hsa-miR-506 probe (Exiqon) on TMA. The LNA U6 snRNA probe was used as a positive control for every case. Immunohistochemical staining was performed for N-cad, vimentin, SNAI2, and E-cad on the same TMA. The results of the statistical analyses are shown in Table 2 . Representative images of all markers were taken at 400× magnification and shown on the basis of high and low miR-506 expression in high-grade serous (A), endometrioid (B), mucinous (C), and clear cell (D) OvCa. Scale bars = 50 μm.
including the 92 serous OvCa cases that were used in our previous study [14] . Although snail transcriptional factors (SNAI1/2) have been detected in both cytoplasm and nucleus [22] [23] [24] , we focused our quantification of nuclear SNAI2 pertaining to its function as a nuclear transcriptional suppression of E-cad. MiR-506 expression could be evaluated in 99 serous, 74 endometrioid, 9 mucinous, 8 clear cell, 4 mixed, and 2 undifferentiated OvCa cases. In serous OvCa, miR-506 expression was negatively correlated with SNAI2 and vimentin and positively correlated with E-cad ( Figure 3A and Table 2 ), which was consistent with the findings of our previous report [14] . Furthermore, the negative correlation was found between miR-506 and N-cad expression in serous OvCa ( Figure 3A and Table 2 ). The same correlations of miR-506 expression with EMT proteins were found in endometrioid OvCa ( Figure 3B and Table 2 ). Although our study included a limited number of cases, similar correlations or trends were observed in mucinous and clear cell OvCa (Figures 3C, 3D , and Table 2 ). Altogether, miR-506 expression was associated with decreased vimentin, N-cad, and SNAI2 expression and increased E-cad expression in the whole cohort of EOC cases (Table 2) .
High miRNA-506 expression is associated with early FIGO stage and longer survival in EOC patients
With the expanded cohort of all the major subtypes of EOC, we analysed the relationships between miR-506 and clinicopathological parameters in EOC patients. The levels of miR-506 expression were comparable among different EOC subtypes or grades (p > 0.05, Supplementary Table 1) . High levels of miR-506 expression were associated with early FIGO stage in serous (p = 0.013, Figure 4A ) and endometrioid OvCa (p = 0.036, Figure 4B ), as well as all EOC cases (p = 0.001, Figure 4C and Supplementary Table 1) . Our previous study demonstrated that high miR-506 level, as estimated by qRT-PCR, was associated with longer survival in high-grade serous OvCa [14] . Here, our results showed that higher miR-506 expression was significantly correlated with longer overall survival (OS) and progression-free survival (PFS) in all EOC patients (p = 0.001, Figure 4D ; p = 0.001, Figure 4G ). Because miR-506 expression was correlated with stage ( Figure 4C , Supplementary high miR-506 expression exhibited a trend of longer OS than those with low miR-506 expression in both stages (p = 0.070, Figure 4E ; p = 0.051, Figure 4F) . Furthermore, the patients with high miR-506 expression had longer PFS than those with low miR-506 expression in both stage II and advanced stages (p = 0.033, Figure 4H ; p = 0.047, Figure 4I ). These results suggested that miR-506 down-regulation accompanies the progression of EOC and that miR-506 can be used as a prognostic predictor for EOC patients.
Systemic delivery of miR-506 suppresses invasion and metastasis of EOC cells in mouse models
To determine the effect of miR-506 on EOC progression, we established EOC orthotopic mouse models by intraperitoneally injecting mice with two EOC cell lines (SKOV3-IP1 and HeyA8-IP2) and treating them with miR-506-DOPC or miR-Ctrl-DOPC. Compared with miR-Ctrl-DOPC treatment, miR-506-DOPC treatment led to decreased VIM and SNAI2 and increased E-cad expression, as well as significant tumour suppression in both mouse models [14] . In this study, we examined the N-cad expression in tumours using immunohistochemical staining and verified that miR-506 also down-regulated N-cad ( Figures 5A and 5B ). To further determine whether miR-506 can inhibit EOC dissemination in orthotopic mouse models, we carefully examined the organs in the pelvic and abdominal cavities. The mesentery, omentum, peri-hepar, peri-spleen, diaphragm, peritoneum, retroperitoneum, ovaries, and pelvis were involved by EOC cells (Supplementary  Table 3 and Figures 5C and 5D) . Compared with the miR-Ctrl treatment groups, the miR-506 treatment groups had fewer invaded organs (p = 0.152 for SKOV3, p = 0.010 for HeyA8, Figure 5E ). In addition, liver metastasis was only found in two mice that had been injected with HeyA8-IP2 cells and treated with miR-Ctrl (Figures 5F and 5G). No liver metastasis was found in either miR-506 treatment group. Together with the previous results [14] , our orthotopic mouse models showed that miR-506 reduced the expression of VIM, N-cad, and SNAI2; increased the expression of E-cad; and eventually inhibited EOC invasion and metastasis.
Discussion
EMT is regulated by complex networks that involve both transcriptional and post-transcriptional regulation [8, 9, 14] . In our previous study, we established that miR-506 is a key suppressor of EMT by directly targeting three binding sites on the 3'-UTR of SNAI2, a transcript suppressor of E-cad, thus increasing E-cad expression [14] . In the present study, we tested and validated a broader role for miR-506 in the suppression of EMT through the direct regulation of two recognized mesenchymal marker proteins, vimentin and N-cad. Therefore, miR-506 has emerged as a key network gatekeeper for epithelial and mesenchymal lineage switches by simultaneously regulating multiple nodes in the sophisticated regulatory network, as we have illustrated in a model ( Figure 6 ). This model is a simplified version that will likely be modified in future studies. For example, our recent study showed that miR-506 inhibited the expression of Forkhead box protein M1 (FoxM1) through directly down-regulating CDK4/CDK6 [25] . FoxM1 was reported to be a transcriptional activator of SNAI1, another major E-cad repressor [26, 27] . Therefore, miR-506 increases E-cad expression through multiple paths. In a recent publica and induce N-cad expression during EMT of melanoma cells [29] . Vimentin expression was also reported to be transactivated by NFκB [30] . Although we consider E-cad and vimentin/N-cad to be the two spectra of EMT/MET, key proteins in these two processes have close crosstalk and there must be extensive feedback regulations between them. In the present study, we found that the knockdown of vimentin up-regulated E-cad expression. It was reported by Rodriguez et al that vimentin inhibited E-cad and induced EMT through GSK-3β, which is an upstream regulator of SNAI1 [31] . Therefore, miR-506 represents a gatekeeper class of EMT inhibitory microRNAs that target multiple key node genes that patrol the EMT network. A second major finding of this study is that vimentin is not just an indicator or marker for EMT. We demonstrated that the knockdown of vimentin alone was sufficient to suppress EMT in EOC cells, including increasing E-cad expression and cell-cell adhesion, inducing actin cytoskeleton reorganization, causing more epithelial morphological characteristics, and inhibiting cell migration and invasion. Rodriguez et al also found that vimentin expression was sufficient to induce increased mesenchymal and pro-metastatic phenotypical changes in melanoma cells, including ILK/GSK-3β-dependent E-cad down-regulation, Snail1 activation, and increased cell motility and migration [31] . Therefore, vimentin may be directly involved in the modulation of EMT and may play an important role in cancer progression. The results of our in vitro cell-based studies suggested a weaker role of N-cad in EMT and the cell migration and invasion process. It should be noted that N-cad is known to mediate the cell-stromal interaction [32] . The current experimental systems do not sufficiently consider the stromal component, which may explain the weaker effect observed in our experiments. Future experiments that include multiple cellular components (eg tumour cells and fibroblast co-cultures) should be able to better determine the role of N-cad.
Consistent with the in vitro results, miR-506 was associated with blocked EMT in all major subtypes of EOC in this study. Although EOC is considered a heterogeneous disease, the majority of EOC patients were diagnosed at advanced stages with intraperitoneal dissemination and metastasis. Therefore, miR-506 may exert a multifaceted anti-metastatic effect to counteract the progression of all major subtypes of EOC. In addition, the role of miR-506 in EMT inhibition and in cell senescence and differentiation was recently demonstrated in several cancer types, including ovarian, breast, lung, and cervical cancer and neuroblastoma [14, 25, 28, [33] [34] [35] . Our previous and present studies showed that miR-506, when delivered through a nanoparticle vehicle, effectively reduced the tumour burden and inhibited invasive growth and metastasis in EOC orthotopic mouse models. The nanoparticle-mediated delivery of tumour-suppressive miRNAs has been actively explored as a new strategy for cancer therapeutics [16, 36, 37] . Therefore, miR-506 may represent a promising new therapeutic agent that can be carried by this new tool to suppress EMT and cancer progression in a broad spectrum of cancer types. Figure 6 . Summary of the role of miR-506 as a potent EMT inhibitor through targeting multiple EMT-related genes. MiR-506 directly targets SNAI2 [14] , CDK4/CDK6 [25] , vimentin, and N-cad. MiR-506 down-regulates SNAI2 and subsequently promotes cell-cell adherence via increasing E-cad expression. MiR-506 inhibits the expression of FoxM1 by directly down-regulating CDK4/CDK6, which decreases the activity of SNAI1 and eventually increases E-cad expression and decreases N-cad expression. Moreover, miR-506 directly down-regulates vimentin and N-cadherin, which reduces cell mobility and cell-matrix adherence. In addition, down-regulation of vimentin induces E-cadherin and increases cell-cell adherence. As a result, miR-506 suppresses EMT and cancer progression in EOC.
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